Skip to main content
Top
Published in: BMC Immunology 1/2010

Open Access 01-12-2010 | Research article

Peripheral blood T Regulatory cell counts may not predict transplant rejection

Authors: Yuchuan Huang, Juan Shan, Chuntao Zhang, Jie Zhang, Li Feng, Shengfu Li, Youping Li

Published in: BMC Immunology | Issue 1/2010

Login to get access

Abstract

Background

Recent evidence shows that allograft survival rates show a positive correlation with the number of circulating T regulatory cells (Tregs). This study investigated both the number and the cytokine profiles exhibited by Foxp3+ Tregs in blood, spleen and lymph nodes of Lewis rat recipients of BN rat cardiac allografts after a single-dose of Rapamycin (RAPA).

Results

Rats were divided into three groups: control group (containing healthy control and acute rejection group), and recipients treated with a single dose of RAPA on either Day 1 (1D group)or Day 3 (3D group) post-transplant. We analyzed the number of Foxp3+Tregs and the expression of Foxp3 and cytokines in the peripheral blood and the peripheral lymphoid tissues. No difference was found in the numbers of circulating Foxp3+ Tregs between these three groups. RAPA administration significantly increased Foxp3 expression in peripheral lymphoid tissues after a single dose of RAPA on Day 3 post-transplant. Foxp3+Tregs inhibited the activity of effector T cells (Teff) via the secretion of TGF-β1.

Conclusion

The number of Tregs in the recipient's blood may not be a good predictor of transplant rejection. Foxp3+Tregs inhibit the activity of Teff cells mainly in the peripheral lymphoid tissues.
Appendix
Available only for authorised users
Literature
1.
go back to reference Wang ME, Stepkowski SM, Ferraresso M, Kahan BD: Evidence that rapamycin rescue therapy delays rejection of major (MHC) plus minor (non-MHC) histoincompatible heart allografts in rats. Transplantation. 1992, 54 (4): 704-709.CrossRefPubMed Wang ME, Stepkowski SM, Ferraresso M, Kahan BD: Evidence that rapamycin rescue therapy delays rejection of major (MHC) plus minor (non-MHC) histoincompatible heart allografts in rats. Transplantation. 1992, 54 (4): 704-709.CrossRefPubMed
2.
go back to reference Poston RS, Billingham M, Hoyt EG, Pollard J, Shorthouse R, Morris RE, Robbins RC: Rapamycin reverses chronic graft vascular disease in a novel cardiac allograft model. Circulation. 1999, 100: 67-74.CrossRefPubMed Poston RS, Billingham M, Hoyt EG, Pollard J, Shorthouse R, Morris RE, Robbins RC: Rapamycin reverses chronic graft vascular disease in a novel cardiac allograft model. Circulation. 1999, 100: 67-74.CrossRefPubMed
3.
go back to reference Ikonen TS, Gummert JF, Hayase M, Honda Y, Hausen B, Christians U, Berry GJ, Yock PG, Morris RE: Sirolimus (rapamycin) halts and reverses progression of allograft vascular disease in non-human primates. Transplantation. 2000, 70: 969-975. 10.1097/00007890-200009270-00015.CrossRefPubMed Ikonen TS, Gummert JF, Hayase M, Honda Y, Hausen B, Christians U, Berry GJ, Yock PG, Morris RE: Sirolimus (rapamycin) halts and reverses progression of allograft vascular disease in non-human primates. Transplantation. 2000, 70: 969-975. 10.1097/00007890-200009270-00015.CrossRefPubMed
4.
go back to reference Dambrin C, Klupp J, Bîrsan T, Luna J, Suzuki T, Lam T, Stähr P, Hausen B, Christians U, Fitzgerald P, Berry G, Morris R: Sirolimus (Rapamycin) monotherapy prevents graft vascular disease in nonhuman primate recipients of orthotopic aortic allografts. Circulation. 2003, 107: 2369-2374. 10.1161/01.CIR.0000065576.80196.A4.CrossRefPubMed Dambrin C, Klupp J, Bîrsan T, Luna J, Suzuki T, Lam T, Stähr P, Hausen B, Christians U, Fitzgerald P, Berry G, Morris R: Sirolimus (Rapamycin) monotherapy prevents graft vascular disease in nonhuman primate recipients of orthotopic aortic allografts. Circulation. 2003, 107: 2369-2374. 10.1161/01.CIR.0000065576.80196.A4.CrossRefPubMed
5.
go back to reference Gao W, Lu Y, El Essawy B, Oukka M, Kuchroo VK, Strom TB: Contrasting effects of cyclosporine and rapamycin in de novo generation of alloantigen-specific regulatory T cells. Am J Transplant. 2007, 7: 1722-1732. 10.1111/j.1600-6143.2007.01842.x.CrossRefPubMed Gao W, Lu Y, El Essawy B, Oukka M, Kuchroo VK, Strom TB: Contrasting effects of cyclosporine and rapamycin in de novo generation of alloantigen-specific regulatory T cells. Am J Transplant. 2007, 7: 1722-1732. 10.1111/j.1600-6143.2007.01842.x.CrossRefPubMed
6.
go back to reference Wood KJ, Sakaguchi S, Regulatory T: cells in transplantation tolerance. Nature Review Immonology. 2003, 3: 199-210. 10.1038/nri1027.CrossRef Wood KJ, Sakaguchi S, Regulatory T: cells in transplantation tolerance. Nature Review Immonology. 2003, 3: 199-210. 10.1038/nri1027.CrossRef
7.
go back to reference Demirkiran A, Kok A, Kwekkeboom J, Kusters JG, Metselaar HJ, Tilanus HW, van der Laan LJ: Low circulating regulatory T-cell levels after acute rejection in liver transplantation. Liver Transpl. 2006, 12: 277-284. 10.1002/lt.20612.CrossRefPubMed Demirkiran A, Kok A, Kwekkeboom J, Kusters JG, Metselaar HJ, Tilanus HW, van der Laan LJ: Low circulating regulatory T-cell levels after acute rejection in liver transplantation. Liver Transpl. 2006, 12: 277-284. 10.1002/lt.20612.CrossRefPubMed
8.
go back to reference Segundo DS, Ruiz JC, Izquierdo M, Fernández-Fresnedo G, Gómez-Alamillo C, Merino R, Benito MJ, Cacho E, Rodrigo E, Palomar R, López-Hoyos M, Arias M: Calcineurin inhibitors, but not rapamycin, reduce percentages of CD4+CD25+Foxp3+ regulatory T cells in renal transplant recipients. Transplantation. 2006, 82: 550-557. 10.1097/01.tp.0000229473.95202.50.CrossRefPubMed Segundo DS, Ruiz JC, Izquierdo M, Fernández-Fresnedo G, Gómez-Alamillo C, Merino R, Benito MJ, Cacho E, Rodrigo E, Palomar R, López-Hoyos M, Arias M: Calcineurin inhibitors, but not rapamycin, reduce percentages of CD4+CD25+Foxp3+ regulatory T cells in renal transplant recipients. Transplantation. 2006, 82: 550-557. 10.1097/01.tp.0000229473.95202.50.CrossRefPubMed
9.
go back to reference Battaglia M, Stabilini A, Roncarolo MG: Rapamycin selectively expands CD4+CD25+FoxP3+ regulatory T cells. Blood. 2005, 105: 4743-4748. 10.1182/blood-2004-10-3932.CrossRefPubMed Battaglia M, Stabilini A, Roncarolo MG: Rapamycin selectively expands CD4+CD25+FoxP3+ regulatory T cells. Blood. 2005, 105: 4743-4748. 10.1182/blood-2004-10-3932.CrossRefPubMed
10.
go back to reference Shan J, Huang YC, Feng L, Ke NW, Luo L, Li CW, Li YP: A modified technique for heterotopic heart transplantation in rats. Journal of Surgical Research. Shan J, Huang YC, Feng L, Ke NW, Luo L, Li CW, Li YP: A modified technique for heterotopic heart transplantation in rats. Journal of Surgical Research.
11.
go back to reference Ono K, Lindsey ES: Improved technique of heart transplantation in rats. J Thorac Cardiovasc Surg. 1969, 57: 225-229.PubMed Ono K, Lindsey ES: Improved technique of heart transplantation in rats. J Thorac Cardiovasc Surg. 1969, 57: 225-229.PubMed
12.
go back to reference Streit F, Christians U, Schiebel HM, Napoli KL, Ernst L, Linck A, Kahan BD, Sewing KF: Sensitive and specific quantification of sirolimus (rapamycin) and its metabolites in blood of kidney graft recipients by HPLC/electrospray-mass spectrometry. Clin Chem. 1996, 42: 1417-1425.PubMed Streit F, Christians U, Schiebel HM, Napoli KL, Ernst L, Linck A, Kahan BD, Sewing KF: Sensitive and specific quantification of sirolimus (rapamycin) and its metabolites in blood of kidney graft recipients by HPLC/electrospray-mass spectrometry. Clin Chem. 1996, 42: 1417-1425.PubMed
13.
go back to reference Roncarolo MG, Gregori S, Battaglia M, Bacchetta R, Fleischhauer K, Levings MK: Interleukin-10-secreting type 1 regulatory T cells in rodents and humans. Immunological Reviews. 2006, 212: 28-50. Roncarolo MG, Gregori S, Battaglia M, Bacchetta R, Fleischhauer K, Levings MK: Interleukin-10-secreting type 1 regulatory T cells in rodents and humans. Immunological Reviews. 2006, 212: 28-50.
14.
go back to reference Schmidt-Lucke C, Aicher A, Romagnani P, Gareis B, Romagnani S, Zeiher AM, Dimmeler S: Specific recruitment of CD4+CD25+ regulatory T cells into the allograft in heart transplant recipients. Am J Physiol Heart Circ Physiol. 2007, 292: 2425-2431. 10.1152/ajpheart.01197.2006.CrossRef Schmidt-Lucke C, Aicher A, Romagnani P, Gareis B, Romagnani S, Zeiher AM, Dimmeler S: Specific recruitment of CD4+CD25+ regulatory T cells into the allograft in heart transplant recipients. Am J Physiol Heart Circ Physiol. 2007, 292: 2425-2431. 10.1152/ajpheart.01197.2006.CrossRef
15.
go back to reference Meloni F, Cascina A, Paschetto E, Marone Bianco A, Morosini M, Pellegrini C, Fietta A, Vitulo P, Pozzi E, Viganò M: Monocyte chemoattractant protein-1 levels in bronchoalveolar lavage fluid of lung transplanted patients treated with tacrolimus as rescue treatment for refractory acute rejection. Transplant Proc. 2003, 35: 1523-1526. 10.1016/S0041-1345(03)00476-7.CrossRefPubMed Meloni F, Cascina A, Paschetto E, Marone Bianco A, Morosini M, Pellegrini C, Fietta A, Vitulo P, Pozzi E, Viganò M: Monocyte chemoattractant protein-1 levels in bronchoalveolar lavage fluid of lung transplanted patients treated with tacrolimus as rescue treatment for refractory acute rejection. Transplant Proc. 2003, 35: 1523-1526. 10.1016/S0041-1345(03)00476-7.CrossRefPubMed
16.
go back to reference Baan CC, van der Mast BJ, Klepper M, et al.,: Differential effect of calcineurin inhibitors, anti-CD25 antibodies and rapamycin on the induction of FOXP3 in human T cells. Transplantation. 2005, 80: 110-10.1097/01.TP.0000164142.98167.4B.CrossRefPubMed Baan CC, van der Mast BJ, Klepper M, et al.,: Differential effect of calcineurin inhibitors, anti-CD25 antibodies and rapamycin on the induction of FOXP3 in human T cells. Transplantation. 2005, 80: 110-10.1097/01.TP.0000164142.98167.4B.CrossRefPubMed
17.
go back to reference Hara M, Kingsley CI, Niimi M, Read S, Turvey SE, Bushell AR, Morris PJ, Powrie F, Wood KJ: IL-10 is required for regulatory T cells to mediate tolerance to alloantigens in vivo. J Immunol. 2001, 166: 3789-3796.CrossRefPubMed Hara M, Kingsley CI, Niimi M, Read S, Turvey SE, Bushell AR, Morris PJ, Powrie F, Wood KJ: IL-10 is required for regulatory T cells to mediate tolerance to alloantigens in vivo. J Immunol. 2001, 166: 3789-3796.CrossRefPubMed
18.
19.
go back to reference Demirkiran A, Kok A, Kwekkeboom J, Kusters JG, Metselaar HJ, Tilanus HW, van der Laan LJ: Low circulating regulatory T-cell levels after acute rejection in liver transplantation. Liver Transpl. 2006, 12: 277-284. 10.1002/lt.20612.CrossRefPubMed Demirkiran A, Kok A, Kwekkeboom J, Kusters JG, Metselaar HJ, Tilanus HW, van der Laan LJ: Low circulating regulatory T-cell levels after acute rejection in liver transplantation. Liver Transpl. 2006, 12: 277-284. 10.1002/lt.20612.CrossRefPubMed
20.
go back to reference Fryer J, Yatscoff RW, Pascoe EA, Thliveris J: The relationship of blood concentrations of rapamycin and cyclosporine to suppression of allograft rejection in a rabbit heterotopic heart transplant model. Transplantation. 1993, 55: 340-345. 10.1097/00007890-199302000-00021.CrossRefPubMed Fryer J, Yatscoff RW, Pascoe EA, Thliveris J: The relationship of blood concentrations of rapamycin and cyclosporine to suppression of allograft rejection in a rabbit heterotopic heart transplant model. Transplantation. 1993, 55: 340-345. 10.1097/00007890-199302000-00021.CrossRefPubMed
21.
go back to reference Yakimets WJ, Lakey JR, Yatscoff RW, Katyal D, Ao Z, Finegood DT, Rajotte RV, Kneteman NM: Prolongation of canine pancreatic islet allograft survival with combined rapamycin and cyclosporine therapy at low doses: rapamycin efficacy is blood level related. Transplantation. 1993, 56: 1293-1298. 10.1097/00007890-199312000-00001.CrossRefPubMed Yakimets WJ, Lakey JR, Yatscoff RW, Katyal D, Ao Z, Finegood DT, Rajotte RV, Kneteman NM: Prolongation of canine pancreatic islet allograft survival with combined rapamycin and cyclosporine therapy at low doses: rapamycin efficacy is blood level related. Transplantation. 1993, 56: 1293-1298. 10.1097/00007890-199312000-00001.CrossRefPubMed
22.
go back to reference Scheffold A, Murphy KM, Hofer T: Competition for cytokines: Treg cells take all. Nature Immunology. 2007, 8: 1286-1287. 10.1038/ni1207-1285.CrossRef Scheffold A, Murphy KM, Hofer T: Competition for cytokines: Treg cells take all. Nature Immunology. 2007, 8: 1286-1287. 10.1038/ni1207-1285.CrossRef
23.
go back to reference Maynard CL, Harrington LE, Janowski KM, James RO, Carlene LZ, Alexander YR, Casey TW: Regulatory T cells expressing interleukin 10 development from Foxp3+ and Foxp3- precursor cells in the absence of interleukin 10. Nature Immunology. 2007, 8: 931-941. 10.1038/ni1504.CrossRefPubMed Maynard CL, Harrington LE, Janowski KM, James RO, Carlene LZ, Alexander YR, Casey TW: Regulatory T cells expressing interleukin 10 development from Foxp3+ and Foxp3- precursor cells in the absence of interleukin 10. Nature Immunology. 2007, 8: 931-941. 10.1038/ni1504.CrossRefPubMed
24.
go back to reference Dieckmann D, Bruett CH, Ploettner H, Lutz MB, Schuler G: Human CD4(+)CD25(+) regulatory, contact-dependent T cells induce interleukin 10-producing, contact-independent type 1-like regulatory T cells. J Exp Med. 2002, 196: 247-253. 10.1084/jem.20020642.PubMedCentralCrossRefPubMed Dieckmann D, Bruett CH, Ploettner H, Lutz MB, Schuler G: Human CD4(+)CD25(+) regulatory, contact-dependent T cells induce interleukin 10-producing, contact-independent type 1-like regulatory T cells. J Exp Med. 2002, 196: 247-253. 10.1084/jem.20020642.PubMedCentralCrossRefPubMed
25.
go back to reference Jonuleit H, Schmitt E, Stassen M, Tuettenberg A, Knop J, Enk AH: Identification and functional characterization of human CD4(+)CD25(+) T cells with regulatory properties isolated from peripheral blood. J Exp Med. 2001, 193: 1285-1294. 10.1084/jem.193.11.1285.PubMedCentralCrossRefPubMed Jonuleit H, Schmitt E, Stassen M, Tuettenberg A, Knop J, Enk AH: Identification and functional characterization of human CD4(+)CD25(+) T cells with regulatory properties isolated from peripheral blood. J Exp Med. 2001, 193: 1285-1294. 10.1084/jem.193.11.1285.PubMedCentralCrossRefPubMed
26.
go back to reference Levings MK, Sangregorio R, Sartirana C, Moschin AL, Battaglia M, Orban PC, Roncarolo MG: Human CD25+CD4+ T suppressor cell clones produce transforming growth factor beta, but not interleukin 10, and are distinct from type 1 T regulatory cells. J Exp Med. 2002, 196: 1335-1346. 10.1084/jem.20021139.PubMedCentralCrossRefPubMed Levings MK, Sangregorio R, Sartirana C, Moschin AL, Battaglia M, Orban PC, Roncarolo MG: Human CD25+CD4+ T suppressor cell clones produce transforming growth factor beta, but not interleukin 10, and are distinct from type 1 T regulatory cells. J Exp Med. 2002, 196: 1335-1346. 10.1084/jem.20021139.PubMedCentralCrossRefPubMed
27.
go back to reference Maloy KJ, Salaun L, Cahill R, Dougan G, Saunders NJ, Powrie F: CD4+CD25+ T(R) cells suppress innate immune pathology through cytokine-dependent mechanisms. J Exp Med. 2003, 197: 111-119. 10.1084/jem.20021345.PubMedCentralCrossRefPubMed Maloy KJ, Salaun L, Cahill R, Dougan G, Saunders NJ, Powrie F: CD4+CD25+ T(R) cells suppress innate immune pathology through cytokine-dependent mechanisms. J Exp Med. 2003, 197: 111-119. 10.1084/jem.20021345.PubMedCentralCrossRefPubMed
28.
go back to reference Gorelik L, Constant S, Flavell RA: Mechanism of transforming growth factor beta-induced inhibition of T helper type 1 differentiation. J Exp Med. 2002, 195: 1499-1505. 10.1084/jem.20012076.PubMedCentralCrossRefPubMed Gorelik L, Constant S, Flavell RA: Mechanism of transforming growth factor beta-induced inhibition of T helper type 1 differentiation. J Exp Med. 2002, 195: 1499-1505. 10.1084/jem.20012076.PubMedCentralCrossRefPubMed
Metadata
Title
Peripheral blood T Regulatory cell counts may not predict transplant rejection
Authors
Yuchuan Huang
Juan Shan
Chuntao Zhang
Jie Zhang
Li Feng
Shengfu Li
Youping Li
Publication date
01-12-2010
Publisher
BioMed Central
Published in
BMC Immunology / Issue 1/2010
Electronic ISSN: 1471-2172
DOI
https://doi.org/10.1186/1471-2172-11-40

Other articles of this Issue 1/2010

BMC Immunology 1/2010 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.